The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynairgen Share News (SNG)

Share Price Information for Synairgen (SNG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6.20
Bid: 5.52
Ask: 7.00
Change: 0.08 (1.31%)
Spread: 1.48 (26.812%)
Open: 6.20
High: 6.20
Low: 6.20
Prev. Close: 6.12
SNG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Small caps round-up: Griffin Mining, Energy XXI

Thu, 06th May 2010 12:49

Griffin Mining posted a rise in profits in the year to December 31 despite a slide in revenues following the collapse in metals prices in late 2008.The company, which operates the Caijiaying zinc-gold mine in China, posted a pre-tax profit of $7.2m, up from $7m in 2008, even as revenues fell to $25.4m from $32.1m.Griffin said it shut down Caijiaying in the first half the year, which enabled it to improve the mine's efficiency once it re-opened in the second half and metals prices had recovered.Bermuda-based oil group Energy XXI saw third quarter earnings before interest, taxes, depreciation, depletion and amortization rise by a third from the same period a year ago to $87.3m.'This quarter's results benefitted from our December consolidation of interests in our key Gulf of Mexico shelf properties and reflect the advantage of having an oil-focused production portfolio,' chairman and chief executive John Schiller said.Investors have welcomed news that respiratory disease drug developer Synairgen's inhaled interferon beta (IFN-beta) to treat rhinovirus infections in asthma and chronic obstructive pulmonary disease (COPD) has been granted in Europe."The European patent grant and the US patent granted last year are key ingredients in the out-licensing package," said chief executive Richard Marsden.Deltex Medical, whose Oesophageal Doppler monitoring equipment is used to measure blood flow in surgery patients, has received a forward order for probes worth at least $204,000 over the next six months. The disposable probes, used with Deltex's CardioQ-ODM system, are placed into the oesophagus through either the mouth or nose and help calculate how quickly blood is flowing. A reduction in circulating blood volume can be deadly.South Africa-focused ferrochrome producer International Ferro Metals, which has its head office in Sydney, thinks it will not be affected by Australia's proposals for a supertax on mining companies.'As all of IFL's operations and resources are located in South Africa with no mining activities undertaken in Australia, IFL believes, having consulted with its advisors, that it will not be liable for the newly proposed resource rent tax,' it says. Personnel software provider Allocate Software has bought Dynamic Change, a compliance and performance management software developer focused on the UK healthcare market. Allocate will pay up to £9m over three years for Dynamic Change, with £4.9m in cash and £0.1m in shares being paid upfront. The company is being acquired with cash balances and receivables of around £1.6m, largely reflecting deferred income which arises from subscriptions paid annually in advance. Clapham House, the restaurant group that owns the Gourmet Burger Kitchen (GBK) brand, is to raise £2.2m from a placing of 3.73m shares at 60p each. The funds will be used to accelerate the expansion of the GBK chain.Product development software specialist Sopheon has sealed 12 new and extension licence orders so far in 2010. Since the company's last trading update on 24 March revenue visibility for the full year from contracted business and recurring revenue streams has risen to £5.6m from £4.8m.
More News
20 Jan 2021 21:16

IN BRIEF: Synairgen Recruits Covid-19 Patients Into Phase II Trial

IN BRIEF: Synairgen Recruits Covid-19 Patients Into Phase II Trial

Read more
13 Jan 2021 10:24

Synairgen Doses First Patient In Covid-19 Treatment Trial

Synairgen Doses First Patient In Covid-19 Treatment Trial

Read more
11 Jan 2021 20:54

COVID SCIENCE-COVID-19 patients still have symptoms 6 months later; interferon may be helpful treatment after all

By Nancy LapidJan 11 (Reuters) - The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.Half a year later, COVID-19 pat...

Read more
18 Dec 2020 12:08

LONDON MARKET MIDDAY: FTSE 100 Rises As Crunch Brexit Talks Dent Pound

LONDON MARKET MIDDAY: FTSE 100 Rises As Crunch Brexit Talks Dent Pound

Read more
18 Dec 2020 11:06

Synairgen Gets Fast Track Designation From US FDA For Covid-19 Vaccine

Synairgen Gets Fast Track Designation From US FDA For Covid-19 Vaccine

Read more
18 Dec 2020 10:29

Synairgen makes solid progress with Covid-19 treatment

(Sharecast News) - Respiratory drug development company Synairgen updated the market on its phase 3 trial design evaluating SNG001 as a treatment for patients with Covid-19 on Friday, as well as positive progress on its regulatory path.

Read more
18 Nov 2020 13:59

finnCap Interim Profit More Than Doubles; Chair To Step Down

finnCap Interim Profit More Than Doubles; Chair To Step Down

Read more
13 Nov 2020 14:28

Synairgen surges on positive results for Covid-19 treatment

(Sharecast News) - Synairgen shares surged on Friday after data from trials of its inhaled Covid-19 treatment, SNG001, published in The Lancet Respiratory Medicine, showed positive results in hospitalised patients.

Read more
13 Nov 2020 10:24

Synairgen Drug Helps Recovery In Hospitalised Covid-19 Patients

Synairgen Drug Helps Recovery In Hospitalised Covid-19 Patients

Read more
2 Nov 2020 20:03

UK TRADING UPDATE SUMMARY: Sensyne App Used In Oxford Covid Study

UK TRADING UPDATE SUMMARY: Sensyne App Used In Oxford Covid Study

Read more
15 Oct 2020 11:39

Synairgen Raises GBP80 Million In Placing, To Launch Open Offer

Synairgen Raises GBP80 Million In Placing, To Launch Open Offer

Read more
14 Oct 2020 18:02

IN BRIEF: Synairgen Looks To Raise GBP80 Million For SNG001 Trial

IN BRIEF: Synairgen Looks To Raise GBP80 Million For SNG001 Trial

Read more
29 Sep 2020 12:14

Synairgen Progresses Covid-19 Treatment As Expenses Increase

Synairgen Progresses Covid-19 Treatment As Expenses Increase

Read more
9 Sep 2020 16:04

IN BRIEF: Synairgen Makes Inhaled Interferon Beta Patent Application

IN BRIEF: Synairgen Makes Inhaled Interferon Beta Patent Application

Read more
9 Sep 2020 12:23

Synairgen files for another patent on 'SNG001'

(Sharecast News) - Respiratory drug development company Synairgen updated the market on its intellectual property for the wholly-owned inhaled interferon beta asset 'SNG001' on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.